Table 1.
Individual participant characteristics of included studies.
| Trial name | Clinical Trial No | Blinding | Study duration | Trial Phase | Study arms | Sample Size, n | Baseline age (years) | Baseline BMI(kg/m2) | Female, n (%) |
|---|---|---|---|---|---|---|---|---|---|
| Blundell 2017 |
NCT02079870 | Double-blind | 12 weeks | Phase 1 | Semaglutide 1·0 mg | 30 | 42 | 33·8 | 10 (33·3) |
| Placebo | 28 | ||||||||
| Lingvay 2018 |
NCT02461589 | Double-blind | 26 weeks | Phase 2 | Semaglutide 1·4 mg | 65 | 58·4 ± 9·6 | 32·8 ± 4·5 | 22 (33·9) |
| Semaglutide 2·1 mg | 63 | 54·8 ± 9·7 | 33·1 ± 4·7 | 31 (49·2) | |||||
| Placebo | 129 | 57·1 ± 9·2 | 32·8 ± 4·2 | 57 (44·2) | |||||
| ONeil 2018 |
NCT02453711 | Double-blind | 52 weeks | Phase 2 | Semaglutide 1·4 mg | 103 | 44 ± 11 | 40·1 ± 6·9 | 66 (64·1) |
| Semaglutide 2·1 mg | 103 | 47 ± 12 | 39·6 ± 7·1 | 66 (64·1) | |||||
| Semaglutide 2·8 mg | 102 | 48 ± 13 | 39·9 ± 8·8 | 66 (64·7) | |||||
| Placebo | 136 | 46 ± 13 | 40·1 ± 7·2 | 88 (64·7) | |||||
| Newsome 2020 |
NCT02970942 | Double-blind | 72 weeks | Phase 2 | Semaglutide 1·4 mg | 78 | 58·1 ± 9·9 | 35·6 ± 6·1 | 52 (67.0) |
| Semaglutide 2·8 mg | 82 | 54·3 ± 10·2 | 35·2 ± 6·6 | 47 (57.0) | |||||
| Placebo | 80 | 52·4 ± 10·8 | 36·1 ± 6·6 | 44 (55.0) | |||||
| Jensterle 2021 |
NCT04263415 | Single-blind | 16 weeks | Phase 4 | Semaglutide 1·0 mg | 15 | 33·7 ± 5·3 | 36·8 ± 3·9 | 13 (100·0) |
| Placebo | 15 | 35·4 ± 3·8 | 12 (100·0) | ||||||
| Flint 2021 |
NCT03357380 | Double-blind | 72 weeks | Phase 2 | Semaglutide 2·8 mg | 34 | 59·5 ± 10·1 | NA | 11 (32·4) |
| Placebo | 33 | 60·5 ± 8·5 | NA | 9 (27·3) | |||||
| Friedrichsen 2021 |
NCT03842202 | Double-blind | 20 weeks | Phase 1 | Semaglutide 2·4 mg | 36 | 40·7 ± 12·2 | 34·2 ± 3·0 | 12 (33·3) |
| Placebo | 36 | 45·0 ± 9·5 | 34·6 ± 3·1 | 16 (44·4) | |||||
| Wadden 2021 |
NCT03611582 | Double-blind | 68 weeks | Phase 3 | Semaglutide 2·4 mg | 407 | 46 ± 13 | 38·1 ± 6·7 | 315 (77·4) |
| Placebo | 204 | 46 ± 13 | 37·8 ± 6·9 | 180 (88·2) | |||||
| Wilding 2021 |
NCT03548935 | Double-blind | 68 weeks | Phase 2 | Semaglutide 2·4 mg | 1306 | 46 ± 13 | 37·8 ± 6·7 | 955 (73·1) |
| Placebo | 655 | 47 ± 12 | 38·0 ± 6·5 | 498 (76·0) | |||||
| Davies 2021 |
NCT03552757 | Double-blind | 68 weeks | Phase 3 | Semaglutide 1·0 mg | 403 | 56 ± 10 | 35·3 ± 5·9 | 203 (50·4) |
| Semaglutide 2·4 mg | 404 | 55 ± 11 | 35·9 ± 6·4 | 223 (55·2) | |||||
| Placebo | 403 | 55 ± 11 | 35·9 ± 6·5 | 190 (47·1) | |||||
| Kadowaki 2022 |
NCT03811574 | Double-blind | 68 weeks | Phase 1 | Semaglutide 1·7 mg | 101 | 51 ± 10 | 31·6 ± 3·7 | 37 (37.0) |
| Semaglutide 2·4 mg | 199 | 52 ± 12 | 32·0 ± 4·6 | 85 (43.0) | |||||
| Placebo | 101 | 50 ± 9 | 31·9 ± 4·2 | 26 (26.0) | |||||
| Rubino 2022 |
NCT04074161 | Double-blind | 68 weeks | Phase 3 | Semaglutide 2·4 mg | 126 | 48 ± 14 | 37·0 ± 7·4 | 102 (81·0) |
| Placebo | 85 | 51 ± 12 | 38·8 ± 6·5 | 66 (77·6) | |||||
|
NCT03693430 2022 |
NCT03693430 | Double-blind | 104 weeks | Phase 3 | Semaglutide 2·4 mg | 152 | 47 ± 12 | NA | 123 (80·9) |
| Placebo | 152 | 47 ± 10 | NA | 113 (74·3) |
NCT, national clinical trial; NA, not available.